AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announced today the closing of the SEK 50 M second tranche of its SEK 150 M Series A financing round. As announced in September 2022, the series A was co-led by Flerie Invest AB (Flerie) and Industrifonden, and where 3B Future Health Fund (3BFHF) joined Flerie and Industrifonden to complete the round together with the founding investor Karolinska Development AB and current investors Fredrik and Ann-Helene Ljungström.
The raised funds will be used to progress development of AnaCardio ́s lead asset AC01, including the GOAL-HF1 study, a phase 1b/2a clinical trial in heart failure patients that is now ongoing in Europe.
”Closing the second tranche of the Series A round marks another milestone for AnaCardio, and highlights the progress we are making in the development of this important and novel treatment concept in heart failure.”, commented Patrik Strömberg, CEO of AnaCardio.
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is an oral ghrelin peptidomimetic small-molecule is being developed as a contractile agent in heart failure patients.
You can find more information about AnaCardio at www.anacardio.com.
For further information, please contact Patrik Strömberg, CEO
Telephone: +46 704 156 159